| abstract |
Xanthine crystallization inhibitors. The present invention relates to a compound of formula (1), a pharmaceutically acceptable salt or solvate thereof, wherein R1 is H or a (C1-C3)alkyl group, R2 is H or a (C1-C3)alkyl group. ), R3 is H or a (C1-C3) alkyl group, with the proviso that at least one of R1, R2 or R3 is a (C1-C3) alkyl group, for use in the treatment and/or prevention of xanthine urolithiasis. |